

PATENT COOPERATION TREATY

M.H.

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Assistant Commissioner for Patents
 United States Patent and Trademark
 Office
 Box PCT
 Washington, D.C.20231
 ÉTATS-UNIS D'AMÉRIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 22 December 1999 (22.12.99)	Assistant Commissioner for Patents United States Patent and Trademark Office Box PCT Washington, D.C.20231 ÉTATS-UNIS D'AMÉRIQUE
International application No. PCT/US99/10579	Applicant's or agent's file reference PU3491WO
International filing date (day/month/year) 14 May 1999 (14.05.99)	Priority date (day/month/year) 15 May 1998 (15.05.98)
Applicant LENHARD, James, Martin et al	

1. The designated Office is hereby notified of its election made:

in the demand filed with the International Preliminary Examining Authority on:

17 November 1999 (17.11.99)

in a notice effecting later election filed with the International Bureau on:

2. The election was

was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer Kiwa Mpay Telephone No.: (41-22) 338.83.38
---	---

PATENT COOPERATION TREATY

PCT

31 JUL 2000

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference PU3491WO	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/US99/10579	International filing date (day/month/year) 14 MAY 1999	Priority date (day/month/year) 15 MAY 1998
International Patent Classification (IPC) or national classification and IPC Please See Supplemental Sheet.		
Applicant GLAXO GROUP LIMITED		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.

2. This REPORT consists of a total of 5 sheets.

This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority. (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 0 sheets.

3. This report contains indications relating to the following items:

- I Basis of the report
- II Priority
- III Non-establishment of report with regard to novelty, inventive step or industrial applicability
- IV Lack of unity of invention
- V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI Certain documents cited
- VII Certain defects in the international application
- VIII Certain observations on the international application

Date of submission of the demand 17 NOVEMBER 1999	Date of completion of this report 11 JULY 2000
Name and mailing address of the IPEA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	Authorized officer JA-NA HINES 
Facsimile No. (703) 305-3230	Telephone No. (703) 308-0196

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US99/10579

L Basis of the report

1. This report has been drawn on the basis of (*Substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments*):

 the international application as originally filed. the description, pages (See Attached), as originally filed.

pages _____, filed with the demand.

pages _____, filed with the letter of _____.

pages _____, filed with the letter of _____.

 the claims, Nos. (See Attached), as originally filed.

Nos. _____, as amended under Article 19.

Nos. _____, filed with the demand.

Nos. _____, filed with the letter of _____.

Nos. _____, filed with the letter of _____.

 the drawings, sheets/fig (See Attached), as originally filed.sheets/fig _____, filed with the demand.sheets/fig _____, filed with the letter of _____.sheets/fig _____, filed with the letter of _____.

2. The amendments have resulted in the cancellation of:

 the description, pages None. the claims, Nos. None. the drawings, sheets/fig None.

3. This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box. Additional observations below (Rule 70.2(c)).

4. Additional observations, if necessary:

NONE

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US99/10579

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**1. STATEMENT**

Novelty (N)	Claims <u>(Please See supplemental sheet)</u>	YES
	Claims <u>(Please See supplemental sheet)</u>	NO
Inventive Step (IS)	Claims <u>(Please See supplemental sheet)</u>	YES
	Claims <u>(Please See supplemental sheet)</u>	NO
Industrial Applicability (IA)	Claims <u>(Please See supplemental sheet)</u>	YES
	Claims <u>(Please See supplemental sheet)</u>	NO

2. CITATIONS AND EXPLANATIONS

1. Claims 1-18, 20, 23-28, 30-32, 34, 37-43, 45-47, 49, 52-58, 60, 63, 65-67 and 69-71 lack novelty under PCT Article 33(2) as being anticipated by Paulik et al. (Pharm. Res.). Paulik et al., teaches the development of infrared imaging to measure thermogenesis in cell culture and thermogenic effects of uncoupling protein-2, troglitazone and Beta-adrenoceptor agonists. The authors developed a robust non-invasive technique to measure real time thermogenesis of cells cultured in microtiter plates using infrared thermography. By showing heat production in yeast increased after transforming the cells with mitochondrial uncoupling protein 2 (UCP2) or treating the cells with a mitochondrial uncoupler carbonyl cyanide p-(trifluoromethoxy)phenylhydrazone (FCCP). Also, the method shows a selective beta-adrenoceptor agonist, stimulated an acute thermogenic response in adipocytes and this process was not blocked by the protein synthesis inhibitor, cycloheximide. The data showed increased UCP synthesis resulted in increased thermogenesis in yeast. These results, taken with the high resolution and robustness of the this approach indicate infrared imaging can be adapted to a variety of thermogenic studies using cultured cells. Figure 1 teaches an apparatus which can measure and provide infrared images. Figures 2-5 teach the results achieved after contacting the sample with the test agent and measuring and comparing the results.

Therefore, Paulik et al., teaches the invention of the instant application.

2. Claims 19, 33 and 48 lack an inventive step under PCT Article 33(3) as being obvious over Paulik et al. (pharm. res.) in view of Adachi et al. (US Patent 5,445,157). Paulik et al., has been discussed above, however it does not teach using tumor cells in this method. Adachi et al., teaches a thermographic endoscope which is capable of detecting a temperature distribution in a part under inspection and finding abnormal cells even if the temperature difference between the normal and abnormal cell is small. Thermographic endoscope includes an infrared image forming devices. Abnormal cells evaluated includes cancer cells. The device can also be inserted into a (Continued on Supplemental Sheet.)

Supplemental Box
 (To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: Boxes I - VIII

Sheet 10

CLASSIFICATION:

The International Patent Classification (IPC) and/or the National classification are as listed below:
 IPC(7): H01L 29/04; G01N 7/00, 25/18, 25/08, 27/416, 1/18, 21/62 and US Cl.: 257/59, 72; 436/147, 149, 150, 151, 155, 157, 171

I. BASIS OF REPORT:

This report has been drawn on the basis of the description, pages, 1-50, and sequence listing pages 1-2, as originally filed.
 pages, NONE, filed with the demand.
 and additional amendments:
 NONE

This report has been drawn on the basis of the claims, numbers, 1-71, as originally filed.
 numbers, NONE, as amended under Article 19.
 numbers, NONE, filed with the demand.
 and additional amendments:
 NONE

This report has been drawn on the basis of the drawings, sheets, 1-27, as originally filed.
 sheets, NONE, filed with the demand.
 and additional amendments:
 NONE

V. 1. REASONED STATEMENTS:

The report as to Novelty was positive (YES) with respect to claims 19, 21-22, 29, 33, 35-36, 44, 48, 50-51, 59, 61-62, 64 and 68.

The report as to Novelty was negative (NO) with respect to claims 1-18, 20, 23-28, 30-32, 34, 37-43, 45-47, 49, 52-58, 60, 63, 65-67, 69-71.

The report as to Inventive Step was positive (YES) with respect to claims 29, 44, 59, 61-62, 64, 68.

The report as to Inventive Step was negative (NO) with respect to claims 1-28, 30-32, 45-58, 60, 63, 65-67, 69-71.

The report as to Industrial Applicability was positive (YES) with respect to claims 1-71.

The report as to Industrial Applicability was negative (NO) with respect to claims None.

V. 2. REASONED STATEMENTS - CITATIONS AND EXPLANATIONS (Continued):

body cavity.

Therefore it would have been obvious to analysis cancer cells as taught by Adachi et al., in the method of Paulik et al., because Adachi et al., teaches that it is well known in the art to monitor, measure and compare temperature differences between abnormal cancer cells and normal ones.

3. Claims 21-22, 35-36 and 50-51 lack an inventive step under PCT Article 33(3) as being obvious over Paulik et al., (Pharm Res.) in view of SHARP KABUSHIKI KAISHA, (GB 2,266,182). Paulik et al., has been discussed above, however it does not teach the use of plant or fungal cells. Watsuji et al., teaches data acquisition, processing devices and biosensors for use in the information technology field. Biological macromolecules such as proteins, enzymes, glycoproteins, nucleic acids and products of recombinant technology can be analyzed.

Therefore, it would have been obvious to one of ordinary skill in the art to analyze plant or fungal cells as taught by Watsuji et al., in the method of Paulik et al., because watsuji et al., teaches a variety of cell types can be analyzed.

Claims 29, 44, 59, 61-62, 64 and 68 meet the criteria set out in PCT Article 33(2)-(3) because the prior art does not teach or fairly suggest the claimed invention.

Claims 1-71 meet the criteria set out in PCT Article 33(4) for industrial applicability.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US99/10579

Supplemental Box

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: Boxes I - VIII

Sheet 11

NONE

— NEW CITATIONS —

an
PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ :		A1	(11) International Publication Number:	WO 99/60630
H01L 29/04, G01N 7/00, 25/18, 25/08, 27/416, 1/18, 21/62			(43) International Publication Date:	25 November 1999 (25.11.99)
(21) International Application Number:	PCT/US99/10579		(74) Agents:	LEVY, David, J.; Glaxo Wellcome Inc., Five Moore Drive, P.O. Box 13398, Research Triangle Park, NC 27709-3398 (US) et al.
(22) International Filing Date:	14 May 1999 (14.05.99)			
(30) Priority Data:	60/085,736	15 May 1998 (15.05.98)	US	(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application	US	60/085,736 (CIP)		
	Filed on	15 May 1998 (15.05.98)		
(71) Applicant (for all designated States except US):	GLAXO GROUP LIMITED [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).			
(72) Inventors; and				
(75) Inventors/Applicants (for US only):	LENHARD, James, Martin [US/US]; Glaxo Wellcome Inc., Five Moore Drive, P.O. Box 13398, Research Triangle Park, NC 27709 (US). PAULIK, Mark, Andrew [US/US]; Glaxo Wellcome Inc., Five Moore Drive, P.O. Box 13398, Research Triangle Park, NC 27709 (US).			

(54) Title: INFRARED THERMOGRAPHY

(57) Abstract

The present invention relates, in general, to thermography and, in particular, to a method of using infrared thermography to monitor physiological and molecular events that elicit a thermogenic response in animals (including humans), plants, tissues, cells and cell-free systems. The present method can be used for screening, identifying, and ranking drug candidates for multiple diseases, disorders and conditions.

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Iiberia	SG	Singapore		
EE	Estonia						

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/10579

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :H01L 29/04; G01N 7/00, 25/18, 25/08, 27/416, 1/18, 21/62
US CL :257/59, 72; 436/147, 149, 150, 151, 155, 157, 171

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : NONE

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
ADONIS

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
CAPLUS, APS, BIOSIS, WPIDS, STN

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PAULIK, M.A. et al. Development of Infrared Imaging to Measure Thermogenesis in Cell Culture. FASEB Journal. April 1998, Vol. 12, No. 8, page A1302, #D5, entire document.	1-12, 14-18, 20, 25-26, 28, 30-32, 34, 39, 41-43, 45-47, 49, 54-56, 60-63, 65-67, 69-71
X	PAULIK, M.A. et al. Development of Infrared Imaging to Measure Thermogenesis in Cell Culture: Thermogenic Effects of Uncoupling Protein-2, Troglitazone, and Beth-Adrenoceptor Agonists. Pharm. Res. March 1998, Vol. 15, No. 6, pages 944-949, see entire document.	1-18, 20, 23-28, 30-32, 34, 37-43, 45-47, 49, 52-58, 60, 63, 65-67, 69-71

Further documents are listed in the continuation of Box C.



See patent family annex.

-	Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A"	document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E"	earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O"	document referring to an oral disclosure, use, exhibition or other means		
"P"	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search
31 AUGUST 1999

Date of mailing of the international search report

17 SEP 1999

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231
Facsimile No. (703) 305-3230

Authorized officer
Lorraine T.
JA-NA HINES
Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/10579

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5,445,157 A (ADACHI et al.) 29 August 1995, col 2-3.	1-10, 19, 33, 48
Y	GB 2 266 182 A (SHARP KABUSHIKI KAISHA) 20 October 1993, pages 2-11.	21-22, 35-36, 50-51